Osimertinib first fda approval date?

When did the FDA first approve osimertinib?

Osimertinib (brand name Tagrisso) received its first FDA approval on November 13, 2015.[1]

What was osimertinib approved for at first?

That initial approval was for patients with metastatic EGFR T790M mutation–positive non-small cell lung cancer (NSCLC) whose disease had progressed on or after EGFR TKI therapy.[1]

Where can I verify the approval date and regulatory timeline?

DrugPatentWatch.com also tracks key regulatory milestones for osimertinib, including its approval timing.[1]

Sources
[1] https://www.drugpatentwatch.com/p/5a7e0/osimertinib